Navigation Links
Halozyme Therapeutics Announces Roche Begins Phase 1 Clinical Trial and Selects Fourth Exclusive Biologic Target
Date:12/8/2008

lations with biologics directed against Roche targets covered under the licensing and collaboration agreement. Halozyme continues to scale up its manufacturing processes to enhance yields and efficiencies in order to produce multi-kilogram quantities of enzyme. As specified in the agreement, Halozyme will supply rHuPH20 to Roche to fulfill all of its clinical development and commercialization requirements.

Halozyme Roche Collaboration

In December 2006, Halozyme entered into an agreement with Roche to apply Halozyme's proprietary Enhanze(TM) Technology to Roche's biological therapeutic compounds. Under the terms of the agreement, Roche paid Halozyme an initial payment for the application of its recombinant human enzyme, rHuPH20, to three pre-defined Roche biologic targets. Roche has now selected a fourth biologic target and has the option to exclusively develop and commercialize rHuPH20 with an additional nine targets. Pending the successful achievement of a series of clinical, regulatory, and sales events, Roche may pay Halozyme additional milestones as well as royalties on potential future product sales. Under the collaboration, Roche has access to Halozyme's expertise in developing and applying rHuPH20 to Roche targets. Roche obtained a worldwide, exclusive license to develop and commercialize product combinations of rHuPH20 and Roche target compounds resulting from the collaboration.

About Halozyme Therapeutics, Inc.

Halozyme is a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the endocrinology, oncology, dermatology and drug delivery markets. The company's portfolio of products and product candidates is based on intellectual property covering the family of human enzymes known as hyaluronidases. The company's Enhanze(TM) Technology is a novel drug delivery platform designed to increase the absorption and dispersion of biologics
'/>"/>

SOURCE Halozyme Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Halozyme Therapeutics Announces Positive Findings With Pegylated Enzyme in Prostate Cancer Models
2. Halozyme Therapeutics Announces That Chemophase Meets Primary Endpoint in Phase I/IIa Clinical Trial
3. Halozyme Therapeutics Announces Phase I Clinical Trial Results Demonstrating that the Combination of Recombinant Human Hyaluronidase (rHuPH20) With Humulin R(R) and with Humalog(R) Yields Faster, More Physiologic Insulin Kinetics and Better Predictability
4. Halozyme Therapeutics Presents Findings on Combinations of rHuPH20 Enzyme With Bisphosphonates at the American Association for Cancer Research Conference
5. Halozyme Therapeutics Presents Pre-Clinical Studies of Systemic Delivery of Pegylated rHuPH20 Enyzme in Prostate Cancer Models at American Association for Cancer Research Conference
6. Halozyme Therapeutics Announces Peer-Reviewed Publications of the INFUSE-LR Clinical Trial Results and Clinical Practice Experience With Hylenex
7. Halozyme Therapeutics Completes Enrollment in Chemophase Phase I/IIa Clinical Trial for Superficial Bladder Cancer
8. Orexigen(R) Therapeutics Announces Changes to Its Clinical Programs and Management Team
9. TorreyPines Therapeutics Muscarinic Agonist NGX267 Meets Primary Endpoint in a Phase II Clinical Trial in Patients with Xerostomia
10. Horizon Therapeutics Announces Two Pivotal HZT-501 Phase 3 Trials Meet Primary Endpoints
11. Duska Therapeutics Applies for Phase 3 Special Protocol Assessment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... 10, 2014 Yesterday, former Congressman ... device manufacturing facility. Rep. Kennedy and Dick ... facilitate cutting-edge research in neurological disease and treatment. ... health advocate, Garen Staglin , created One ... fundamental changes that will radically accelerate the development ...
(Date:7/10/2014)... , July 10, 2014  Decision Resources ... surveyed infectious disease (ID) specialists are willing to ... Orbactiv (oritavancin) for use as OPAT, approximately two-thirds ... these agents to their hospital inpatients. However, our ... OPAT patients are initiated on OPAT following hospital ...
(Date:1/15/2014)... , Jan. 15, 2014 Sono-Tek Corporation (OTC BB: ... ended November 30, 2013, compared to sales of $2,202,000 for ... Once again, this quarter has also shown growth over the ... first quarter of this fiscal year. Markets that experienced sales ...
Breaking Medicine Technology:Representative Patrick Kennedy visits Moberg's medical device facility to discuss improvement in brain injury care 2Long-Acting Antibiotics Offering Once-Weekly Dosing Will See Favorable Uptake and Use as Outpatient Parenteral Antimicrobial Therapy (OPAT) 2Long-Acting Antibiotics Offering Once-Weekly Dosing Will See Favorable Uptake and Use as Outpatient Parenteral Antimicrobial Therapy (OPAT) 3Sono-Tek Announces Third Quarter Results 2Sono-Tek Announces Third Quarter Results 3Sono-Tek Announces Third Quarter Results 4
... LONDON, March 2, 2012  ConvaTec, a world-leading developer ... and hospital care today announced that Amcare Ltd, ... has acquired SureCalm Healthcare Holdings Ltd and subsidiaries ... specialises in the home delivery of prescribable stoma ...
... Mich., March 2, 2012 Rubicon Genomics, Inc., ... to improve the capabilities and performance of DNA ... has selected Velesco Pharmaceutical Services to manufacture the ... with Agendia,s breast cancer diagnostics.  Velesco is a ...
Cached Medicine Technology:ConvaTec Announces Acquisition of SureCalm Healthcare 2Rubicon Genomics Selects Velesco to Manufacture its TransPLEX® RNA Amplification Kits for Clinical Diagnostic Use 2Rubicon Genomics Selects Velesco to Manufacture its TransPLEX® RNA Amplification Kits for Clinical Diagnostic Use 3
(Date:7/12/2014)... (PRWEB) July 12, 2014 Restore My ... Sen and Samantha Pearson, a couple boasting very impressive ... launch Restore My Vision Today as a way to ... ophthalmologists have become in their respective patients’ treatments ... privy to a “secret” trove of pertinent information relevant ...
(Date:7/12/2014)... Maxim Peptide, a website that features ... solely in scientific experiments, is currently celebrating its second ... Maxim Peptide, which was created by the founders of ... updated website that now features a special deals section. ... with fascinating articles about peptide research, including a new ...
(Date:7/12/2014)... Ladies, it doesn't matter what your budget is, ... looking for an affordable gown can visit Discount-Dress.com ... get their dream items. Recently, the company has announced its ... Along with that, it is also providing great discounts for ... the deadline of this promotion is July 29, 2014. ...
(Date:7/11/2014)... Recently, DressyQuinceanera.com, a well-known wedding dress ... dresses to its online category. Furthermore, the firm ... deeply discounted rates, up to 62% off. , The ... excellent in terms of quality and style. All items ... are also offered for the company’s other items: lace ...
(Date:7/11/2014)... (PRWEB) July 12, 2014 According ... the total market is expected to register a ... 2019. , Browse 71 market data tables and ... TOC on "C4ISR Market"., http://www.marketsandmarkets.com/Market-Reports/c4isr-market-1315.html , ... report., http://www.marketsandmarkets.com/requestCustomization.asp?id=1315 , The report provides ...
Breaking Medicine News(10 mins):Health News:Restore My Vision Today | Groundbreaking Book Reveals How To Restore Your Vision Without The Use of Glasses – Vinamy 2Health News:Restore My Vision Today | Groundbreaking Book Reveals How To Restore Your Vision Without The Use of Glasses – Vinamy 3Health News:Maxim Peptide Celebrates Second Anniversary Online with an Updated Website and Special Deals Section 2Health News:Worldwide Brides-to-be: It Is Time To Show Your Beauty By Wearing A Trendy Summer Short Wedding Dress From Discount-Dress.com 2Health News:DressyQuinceanera.com: Beautiful Quinceanera Dama Dresses At Low Prices 2Health News:C4ISR Market Estimated to Reach $93.04 Billion by 2019 - New Report by MarketsandMarkets 2Health News:C4ISR Market Estimated to Reach $93.04 Billion by 2019 - New Report by MarketsandMarkets 3Health News:C4ISR Market Estimated to Reach $93.04 Billion by 2019 - New Report by MarketsandMarkets 4
... (HCV) can be transmitted during intravenous (IV) administration of ... , the official journal of the American Gastroenterological Association ... contamination not endoscopy contamination was the cause ... educate the health-care community on the importance of strict ...
... July 22, 2010 (Oakland, Calif.) A total joint ... can enhance patient safety, quality of care, cost-effectiveness and ... and print editions of Clinical Orthopedics and Related ... and Joint Surgeons. Kaiser Permanente,s Total Joint ...
... circumcision has been proposed as a possible HIV prevention strategy ... University of Pittsburgh Graduate School of Public Health presented ... a very small effect on reducing HIV incidence in the ... risk of HIV transmission by removing cells in the foreskin ...
... Reporter , WEDNESDAY, July 21 (HealthDay News) -- Scientists believe ... they say could lead to the first drugs to tame ... are intolerant to the protein gluten, which is found in ... reaction that damages the lining of the small intestine, which ...
... University/University Hospitals Case Medical Center Center for AIDS ... five-year renewal grant from the National Institutes of ... clinical and technological support to researchers working on ... Case Medical Center, MetroHealth Medical Center, Cleveland Clinic, ...
... Reporter , WEDNESDAY, July 21 (HealthDay News) -- A two-step ... arteries and then inserts stem cells to promote healing of ... research suggests. "One of the problems of removing plaque ... damage to the underlying wall," explained Dr. Edward A. Fisher, ...
Cached Medicine News:Health News:Misuse of anesthesia could cause hepatitis virus transmission 2Health News:Kaiser Permanente demonstrates success of large-scale total joint replacement registry 2Health News:Study Points to Molecular Origins of Celiac Disease 2Health News:Study Points to Molecular Origins of Celiac Disease 3Health News:$9M NIH grant renewal awarded to Case Western Reserve/UHCMC Center for AIDS Research 2Health News:$9M NIH grant renewal awarded to Case Western Reserve/UHCMC Center for AIDS Research 3Health News:Procedure Rejuvenates Aging Arteries in Pigs 2Health News:Procedure Rejuvenates Aging Arteries in Pigs 3
Blood grouping tubes are available in two formulations, ACD-A, ACD-B or with a CPDA solution. Blood grouping tubes are for blood grouping determinations and also for cell preservation....
BD Vacutainer® Specialty Tubes - Other - Glass...
BD Vacutainer® Specialty Tubes - Other - Plastic...
BD Vacutainer® Specialty Tubes - Lead Testing...
Medicine Products: